e-learning
resources
ERJ
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia
Siempos I. I., Vardakas K. Z., Manta K. G., Falagas M. E.
Source:
Eur Respir J 2007; 29: 548-560
Journal Issue:
March
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Siempos I. I., Vardakas K. Z., Manta K. G., Falagas M. E.. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007; 29: 548-560
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors
Source: Eur Respir J 2010; 35: 598-615
Year: 2010
VAP: approach to therapy
Source: Eur Respir Mon 2011; 53: 36-47
Year: 2011
Acinetobacter baumannii infection and colonization among pediatric patients in pediatric ICU and other ICUs
Source: International Congress 2018 – Neonatology and paediatric intensive care
Year: 2018
Acinetobacter baumani
and
Pseudomonas aeruginosa
drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICU
Source: Eur Respir J 2003; 22: Suppl. 45, 450s
Year: 2003
Aetiopathogenesis of VAP revisited
Source: Eur Respir Mon 2011; 53: 1-10
Year: 2011
Potential treatment for nosocomial respiratory strains of extreme drug resistant
acinetobacter baumanii
Source: Eur Respir J 2007; 30: Suppl. 51, 410s
Year: 2007
MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia
Source: Eur Respir J 2009; 34: 1470-1476
Year: 2009
Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Source: Eur Respir J 2002; 20: 432-439
Year: 2002
Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobactor baumannii infection
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Prognosis of
Acinetobacter baumannii
bacteraemia in a respiratory ICU: 10 years‘ experience
Source: Eur Respir J 2005; 26: Suppl. 49, 222s
Year: 2005
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Source: Eur Respir J 2007; 30: 307-313
Year: 2007
The mortality of Acinetobacter baumanni infection in intensive care unit
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
New antibiotics for VAP
Source: Eur Respir Mon 2011; 53: 48-53
Year: 2011
Early mortality in patients with community-acquired pneumonia: causes and risk factors
Source: Eur Respir J 2008; 32: 733-739
Year: 2008
Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria
Source: Eur Respir J 2006; 28: Suppl. 50, 786s
Year: 2006
Acinetobacter baumanii and Stenotrophomonas maltophilia are associated with lower airway infections in tracheostomised children and young adults.
Source: International Congress 2017 – New insights into paediatric respiratory infections
Year: 2017
Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial
Source: Eur Respir J 2004; 23: 921-926
Year: 2004
What is MRSA?
Source: Eur Respir J 2009; 34: 1190-1196
Year: 2009
An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by
Pseudomonas aeruginosa
Source: Eur Respir J 2005; 26: Suppl. 49, 187s
Year: 2005
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept